# Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

> **NCT07708961** · PHASE2 · SUSPENDED · sponsor: **Mayo Clinic** · enrollment: 60 (estimated)

## Conditions studied

- Glioblastoma, IDH-Wildtype

## Interventions

- **PROCEDURE:** Archive Sample Retrieval
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Chest Radiography
- **PROCEDURE:** Echocardiography Test
- **DRUG:** EGFR/EGFRvIII Inhibitor WSD0922-FU
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT07708961
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2026-08-28
- **Primary completion:** 2036-08-31
- **Final completion:** 2036-08-31
- **Target enrollment:** 60 (ESTIMATED)
- **Why stopped:** Pending receipt of study drug from sponsor
- **Last updated:** 2026-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07708961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07708961, "Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07708961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*